UNSPSC 51334406: Diclometide

This classification denotes an antipsychotic agent with the molecular formula C14H20Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05186J17EP, chemically known as 3,5-dichloro-n-(2-(diethylamino)-ethyl)-o-anisamide. but generally known as diclometide, which bears US NIH Compound Identifier 208832. European Medicines Agency schedules Diclometide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07096MIG.

UNSPSC 51334406 Diclometide is a Commodity code covering pharmaceutical products and related medical supply procurement by state and local health agencies. The recent opportunities tagged under this code show state and local governments buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive solicitations. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. The scope spans both direct procurement of specialized medical countermeasures (such as naloxone kits for community health programs) and participation in statewide or regional contracts for generic and OTC pharmaceutical distribution through authorized wholesalers.

Recent activity centers in Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a response deadline of July 26, 2023 (note: the posted date and due date are incongruent in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capacity information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 on January 20, 2026, to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with responses due March 26, 2026, and contract effectiveness set for July 1, 2026. Vendors bidding under MMCAP must maintain $5 million in commercial general liability coverage and pay a 3 percent administrative fee on purchases.